Improved insulin-sensitivity in mice heterozygous for PPAR-γ deficiency

Journal of Clinical Investigation

Volumn 105, Issue 3, 2000, Pages 287-292

  Miles, Philip D G ^a,f   Barak, Yaacov ^b   He, Weiman ^c   Evans, Ronald M ^b   Olefsky, Jerrold M ^c,d,e  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^e Whittier Institute for Diabetes   (United States)

^f UCSD MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; FATTY ACID; INSULIN; NOVOLIN R; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; GENE MUTATION; GENETIC MANIPULATION; GLUCOGENESIS; GLUCOSE METABOLISM; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; KNOCKOUT MOUSE; LIVER METABOLISM; MALE; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL;

EID: 0033973843     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI8538     Document Type: Article

References (30)

1. Kliewer, S.A., et al. 1994. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. USA. 91:7355-7359.
2. Tontonoz, P., Hu, E., and Spiegelman, B.M. 1994 Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell. 79:1147-1156.
3. Tontonoz, P., Nagy, L., Alvarez, J.G., Thomazy, V.A., and Evans, R.M. 1998. PPARγ promotes monocyte macrophage differentiation and uptake of oxidized LDL. Cell. 93:241-252.
4. Tontonoz, P., Hu, E., Graves, R.A,. Budavari, A., and Spiegelman, B.M. 1994. mPPARγ2: tissue specific regulator of an adipocyte enhance. Genes Dev. 8:1224-1234.
5. Schoonjans, K., et al. 1996. PPARα and PPARγ activation a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 15:5336-5348.
6. Sears, L.B., MacGinntie. M.A., Kovacs, L.G., and Graves, R.A. 1996. Differentiation-dependent expression of the brown adipocyte uncoupling protein gene: regulation by peroxisome proliferator activated receptor γ, Mol. Cell. Biol. 16:3410-3418.
7. Barak, Y., et al. PPARγ is required for placental, cardiac and adipose tissue development. Mol. Cell. 4:585-595.
8. 1 signaling. Nature. 355:446-449.
9. Marks, M.S., et al. 1992. H-2RIIBP (RXR beta) heterodimerization provides a mechanism for combinational diversity in the regulation of retinoic acid and thyroid hormone responsive genes. EMBO J. 11:1419-1435.
10. Kliewer, S.A., Umesono, K., Noonan, D.J., Heyman, R.A.,and Evans, R.M. 1992. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature. 358:771-774.
11. Mangelsdorf, D.F., et al. 1991. A direct repeat in the cellular retinol-binding protein type II gene confers differential regulation by RXR and RAR. Cell. 66:555-561.
12. 1214-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell. 83:803-812.
13. Kliewer, S.A., et al. 1995. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell. 83:813-819.
14. Nagy, L., Tontonoz, P., Alvarez, J.G., Chen, H., and Evans, R.M. 1998. Oxidized LDL. regulates macrophage gene expression through ligand activation of PPARγ. Cell. 93:229-240.
15. Lehmann, J.M., et al. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. 270:12953-1256.
16. Iwamoto, Y., et al. 1991. Effects of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care. 14:1083-1086.
17. Suter, S.L., Nolan, J.J., Wallace, P., Gumbiner, B., and Olefsky, J.M. 1992. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care. 15:193-203.
18. Nolan, J.J., Ludvik, B., Beerdsen, P., Joyce, M., and Olefsky, J. 1994. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med. 331:1188-1193.
19. Fujiwara, T., Yoshioka, S., Yoshioka, T., Ushiyama, I., and Horikoshi, H. 1988. Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes. 37:1549-1558.
20. Fujiwara, T., et al. 1991. Characterization of CS-045, a new oral antidiabetic agent. II. Effects on glycemic control and pancreatic islet structure in C57BL/KsJ-db/db mice. Metabolism. 40:1213-1218.
21. Lee, M.-K., et al. 1994. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes. 43:1435-1439.
22. Revers, R.R., Fink, R., Griffin, J., Olefsky, J.M., and Kolterman, O.G. 1984. Influence of hyperglycemia on effects in type II diabetes. J. Clin. Invest. 73:664-672.
23. Steele, R. 1959. Influence of glucose loading and of injected insulin on hepatic glucose output. Ann. NY Acad. Sci. 82:420-430.
24. Kubota, N., et al. 1999. PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell. 4:597-609.
25. Zhang, B., et al. 1996. Dow-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice. J.Biol. Chem. 271:9455-9459.
26. Chen, J.D., and Evans, R.M. 1995. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature. 377:454-457.
27. Hèorlein, A.J., et al. 1995. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature. 377:397-404.
28. Nagy, L., et al. 1997. Nuclear receptor repression mediated by a complex containing SMRT, mSIN3A, and histone deacetylase. Cell. 89:373-380.
29. Oberfield, J.L., et al. 1999. A peroxisome proliferator-activated receptor gamma ligand inhibits adiocyte differentiation. Proc. Natl. Acad. Sci. USA. 96:6102-6106.
30. Reginato, M.J. ,et al. 1998. A potent antidiabetic thazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties. J. Biol. Chem. 273:32679-32684.